Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...
Private health insurance premiums will be going up in 2026 — in some cases, by a lot. Congressional Democrats and Republicans ...
WRIC ABC 8News on MSN
Never skip taking weight-loss medications, even during holiday season and health coverage changes: UVA Health
With foodborne illnesses and changes in Medicare and Medicaid coverage, University of Virginia (UVA) Health experts say never ...
Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...
LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight management has undergone a seismic shift. Zealthy is one of the fastest-growing telehealth weight-loss platforms in the ...
The market for GLP-1 drugs is projected to reach $180 billion in 2034, according to Morningstar Equity Research. Current ...
Drugmakers are moving to sell their medicines directly to patients, abandoning the middlemen they have long relied on.
Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...
Employers can join the waitlist today to learn how the company is making high-demand benefits—starting with GLP-1s for obesity management—more affordable for America’s workforceMCLEAN, Va.--(BUSINESS ...
ABP News on MSN
Ozempic-Type Drugs Are Here To Stay, And They’re Reshaping The Global Consumer Economy
They're leading to reduced grocery spending, healthier food choices, wardrobe changes, and altered dining habits. The drugs ...
The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experime ...
Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback